Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273420 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL16741182 | 0.71 | KDM4E (0.36) | BLMNOS1 | |
| SCHEMBL19236409 | 0.70 | NOS1 (0.33) | NOS1 | |
| SCHEMBL2044798 | 0.69 | NOS1 (0.49) | PNPBLMNOS1 | |
| SCHEMBL3454198 | 0.68 | CYP3A4 (0.36) | PNPCYP3A4BLM | |
| SCHEMBL3454164 | 0.68 | NOS1 (0.53) | PNPCYP3A4BLMNOS1 | |
| SCHEMBL7359692 | 0.68 | NOS1 (0.31) | NOS1 | |
| Hydrochloric Acid SCHEMBL28835504 | 0.67 | KDM4E (0.33) | BLMNOS1 | |
| SCHEMBL1860433 | 0.66 | NOS1 (0.64) | PNPNOS1 | |
| Hydrochloric Acid SCHEMBL625930 | 0.64 | ALDH1A1 (0.37) | BLMNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1116721-B1 | Process for the reduction of pterines | CERBIOS PHARMA SA (CH) | 2003-03-12 | — | — | EP | claimed |
| US-6162914-A | Process for the reduction of pterins | CERBIOS-PHARMA S.A. (CH) | 2000-12-19 | — | — | US | claimed |
| JP-7188232-A | — | — | None | — | — | JP | disclosed |
| US-20230241069-A1 | Sapropterin Formulation | APR APPLIED PHARMA RESEARCH SA (CH) | 2023-08-03 | — | — | US | disclosed |
| US-7816525-B1 | Process for the preparation of optically pure tetrahydropterins and derivatives, and specifically of optically pure tetrahydrofolic acid and derivatives thereof, by stereospecific hydrogenation | Merck & Cie (CH) | 2010-10-19 | — | — | US | disclosed |
| US-20080306263-A1 | Process For The Preparation Of Optically Pure Tetrahydropterins And Derivatives, And Specifically Of Optically Pure Tetrahydrofolic Acid And Derivatives Thereof, By Stereospecific Hydrogenation | MULLER HANS RUDOLF | 2008-12-11 | — | — | US | disclosed |
| EP-1200437-B1 | METHOD FOR PRODUCING BY STEREOSPECIFIC HYDRATION TETRAHYDROPTERINS AND OPTICALLY PURE DERIVATIVES, IN PARTICULAR TETRAHYDROFOLIC ACID AND ITS OPTICALLY PURE DERIVATIVES | EPROVA AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| EP-1200437-A1 | METHOD FOR PRODUCING BY STEREOSPECIFIC HYDRATION TETRAHYDROPTERINS AND OPTICALLY PURE DERIVATIVES, IN PARTICULAR TETRAHYDROFOLIC ACID AND ITS OPTICALLY PURE DERIVATIVES | EPROVA AG Forschungsinstitut (CH) | 2002-05-02 | — | — | EP | disclosed |
| EP-1116721-A1 | Process for the reduction of pterines | Cerbios-Pharma S.A. (CH) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001004120-A1 | METHOD FOR PRODUCING BY STEREOSPECIFIC HYDRATION TETRAHYDROPTERINS AND OPTICALLY PURE DERIVATIVES, IN PARTICULAR TETRAHYDROFOLIC ACID AND ITS OPTICALLY PURE DERIVATIVES | EPROVA AG (CH) | 2001-01-18 | — | — | WO | disclosed |
| US-6162914-A | Process for the reduction of pterins | CERBIOS-PHARMA S.A. (CH) | 2000-12-19 | — | — | US | disclosed |
| US-6162914-A | Process for the reduction of pterins | CERBIOS-PHARMA S.A. (CH) | 2000-12-19 | — | — | US | disclosed |
| JP-H07188232-A | CELL DAMAGE SUPPRESSING AGENT | ASAHI BREWERIES LTD | 1995-07-25 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306263-A1 | Process For The Preparation Of Optically Pure Tetrahydropterins And Derivatives, And Specifically Of Optically Pure Tetrahydrofolic Acid And Derivatives Thereof, By Stereospecific Hydrogenation | DHFR, MTHFD2, MTHFD1 | PNP 1054/4885CYP3A4 193/4885BLM 2462/4885 |
| US-20230241069-A1 | Sapropterin Formulation | PSAP, CYP46A1, HSD11B2 | PNP 2755/4885CYP3A4 579/4885BLM 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.